5α,6α-epoxyandrostan-17-one | 131768-89-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 5α,6α-epoxyandrostan-17-one
• 英文别名: 5α,6α-epoxyandrost-17-one；5alpha,6alpha-Epoxyandrostan-17-one；(1S,2R,7R,9S,11R,12S,16S)-2,16-dimethyl-8-oxapentacyclo[9.7.0.02,7.07,9.012,16]octadecan-15-one
• CAS: 131768-89-3
• 化学式: C₁₉H₂₈O₂
• 分子量: 288.43
• InChiKey: BHHBZAJAJWISAZ-QXROXWLYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  29.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5α,6α-epoxyandrostan-17-one 在 吡啶 、 sodium hydroxide 、 氯化亚砜 、 间氯过氧苯甲酸 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 51.75h， 生成 4α,5α-Epoxy-6β-hydroxyandrostan-17-one
  参考文献：
  名称：

  Flaih, Nazar; Hanson, James R., Journal of the Chemical Society. Perkin transactions I, 1990, # 10, p. 2667 - 2669

  摘要：

  DOI：
• 作为产物：
  描述：

  5-androsten-17-one 在 间氯过氧苯甲酸 作用下， 以 氯仿 为溶剂， 反应 1.0h， 以6.1 g的产率得到5α,6α-epoxyandrostan-17-one
  参考文献：
  名称：

  Flaih, Nazar; Hanson, James R., Journal of the Chemical Society. Perkin transactions I, 1990, # 10, p. 2667 - 2669

  摘要：

  DOI：

文献信息

• Heterocyclic Compounds as MEK Inhibitors
  申请人：Chikkanna Dinesh

  公开号：US20090275606A1

  公开（公告）日：2009-11-05

  The present invention relates to compounds of formula I and pharmaceutically acceptable salts. These compounds can act as potential MEK inhibitors in the treatment of hyperproliferative diseases, like cancer and inflammation. The present invention also reveals methods of preparation thereof.

  本发明涉及公式I的化合物和药用盐。这些化合物可以作为潜在的MEK抑制剂，用于治疗癌症和炎症等过度增殖性疾病。本发明还揭示了其制备方法。
• AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS
  申请人：Cerri Alberto

  公开号：US20110053902A1

  公开（公告）日：2011-03-03

  Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na + , K + -ATPase. Said compounds are used for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.

  化合物的化学式（I），其中：所述基团如描述中所定义，可用于制备用于治疗心血管疾病，特别是心力衰竭和高血压的药物。这些化合物是Na+，K+-ATP酶活性的抑制剂。所述化合物用于制备一种药物，用于治疗由内源性欧巴因的高血压效应引起的疾病，例如在常染色体显性多囊肾病（ADPKD）中肾功能衰竭进展、妊娠期高血压和蛋白尿以及具有adducin多态性的患者中的肾功能衰竭进展。
• AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS
  申请人：Cerri Alberto

  公开号：US20090275542A1

  公开（公告）日：2009-11-05

  Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. They are useful for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.

  式(I)化合物，其中：所述基团如描述中定义的那样，对于制备治疗心血管疾病的药物，特别是心力衰竭和高血压是有用的。这些化合物是Na+，K+-ATPase酶活性的抑制剂。它们对于制备治疗内源性欧巴因引起的疾病的药物是有用的，例如：常染色体显性多囊肾病（ADPKD）中的肾功能衰竭进展、先兆子痫性高血压和蛋白尿，以及具有adducin多态性的患者的肾功能衰竭进展。
• Amino derivatives of androstanes and androstenes as medicaments for cardiovascular disorders
  申请人：Cerri Alberto

  公开号：US08609644B2

  公开（公告）日：2013-12-17

  Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. Said compounds are used for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.

  公式（I）的化合物，其中：所述的基团如描述中所定义，用于制备治疗心血管疾病，特别是心力衰竭和高血压的药物。这些化合物是Na+，K+-ATPase酶活性的抑制剂。所述化合物用于制备治疗由内源性欧巴因引起的疾病的药物，如常染色体显性多囊肾病（ADPKD）中的肾衰竭进展，先兆子痫性高血压和蛋白尿以及携带adducin多态性的患者的肾衰竭进展。
• Azaheterocyclyl derivatives of androstanes and androstenes as medicaments for cardiovascular disorders
  申请人：Cerri Alberto

  公开号：US08536160B2

  公开（公告）日：2013-09-17

  Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. They are useful for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.

  式（I）的化合物，其中：所述基团如描述中所定义，用于制备用于治疗心血管疾病，特别是心力衰竭和高血压的药物。这些化合物是Na+，K+-ATPase酶活性的抑制剂。它们用于制备治疗由内源性欧巴因引起的疾病的药物，如常染色体显性多囊肾病（ADPKD）中的肾衰竭进展，先兆子痫性高血压和蛋白尿以及具有加朵因多态性的患者的肾衰竭进展。